Why Titan Pharma's on My Radar This Week

Jun.15.10 | About: Titan Pharmaceuticals, (TTNP)

Titan Pharmaceuticals (NASDAQ:TTNP) is a company and a 'Stock to Watch' this week after shares closed over ten percent to the upside on Monday, most likely in anticipation of a decision by the United States Patent and Trademark Office that is expected to be rendered on Tuesday, June 15th regarding Titan's Probuphine patent.

Any extended patent life for Probuphine would significantly boost the value and future potential of Titan Pharmaceuticals, a company already reaping the 8-10% royalty rewards from the Fanapt licensing agreement. Titan has also been awarded a grant from the National Institutes of Health to cover up to $8 million of the cost of the Probuphine confirmatory Phase III trial.

The Phase III trial is currently recruiting patients, and if all goes as planned, will be completed in July of 2011.

You never expect any government office to meet a deadline - especially when the deadline is self-imposed, but the possibility of a Probuphine patent decision this week makes TTNP a "Stock to Watch."

Disclosure: Long TTNP.OB.